Menopause drug Veozah authorised by FDA to deal with sizzling flashes

14 May

Menopause drug Veozah authorised by FDA to deal with sizzling flashes


  • The Meals and Drug Administration has authorised Veozah (fezolinetant), a drug to deal with signs of menopause.
  • The drug, produced by Tokyo-headquartered Astellas Pharma, was discovered to considerably scale back sizzling flashes and evening sweats that accompany menopause.
  • Veozah is taken into account a serious improvement for menopause therapy as a result of hormonal remedy shouldn’t be viable for all sufferers.

The Meals and Drug Administration has authorised a once-a-day tablet for coping with uncomfortable sizzling flashes introduced on by menopause.

The brand new drug, Veozah (fezolinetant), differs from the standard therapy of boosting the hormones estrogen and progestin to cut back menopause signs, which embody sweating, flushing and chills. Developed by Astellas Pharma, Veozah blocks a chemical within the mind known as neurokinin B (NKB), which regulates physique temperature.

“Sizzling flashes because of menopause generally is a severe bodily burden on ladies and affect their high quality of life,” mentioned Janet Maynard, director of the FDA’s Workplace of Uncommon Ailments, Pediatrics, Urologic and Reproductive Medication, in a press release. “The introduction of a brand new molecule to deal with reasonable to extreme menopausal sizzling flashes will present a further secure and efficient therapy possibility for girls.”